Fig. 2From: Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children studyChange in height standard deviation scores (HSDS) in hormone-naïve patients with growth hormone deficiency (GHD) included in the efficacy analysis set over 5 years. BL, baselineBack to article page